

# INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES

Published by JK Welfare & Pharmascope Foundation Journal Home Page: www.ijrps.com

## **Insights from the interfaces of HIV-1 envelope (ENV) trimer viral protein GP160 (GP120-GP41)**

Christina Nilofer, Arumugam Mohanapriya\*

School of Biosciences and Technology, Vellore Institute of Technology, Vellore Campus, Tiruvalam Road, Katpadi, Vellore, Tamil Nadu - 632014, India



#### \*Corresponding Author

Name: Arumugam Mohanapriya Phone: 9843111639 Email: mohanapriyaa@vit.ac.in

## ISSN: 0975-7538

DOI: https://doi.org/10.26452/ijrps.v12i1.4111

Production and Hosted by

IJRPS | [www.ijrps.com](https://doi.org/10.26452/ijrps.v12i1.4111)

© 2021 *|* All rights reserved.

## **INTRODUCTION**

Regardless of the remarkable efforts to develop a vaccine for HIV-1/AIDS has always been a great challenge over the last decade with disappointing results in clinical trials (Shin, 2016). The unsatisfactory clinical trial results from VaxGen's AIDSVAXgp120 vaccine and MRKAd5 HIV-1 Gag/Pol/Nef have been discussed elsewh[ere \(Adis Ed](#page-9-0)itorial, 2003; Überla, 2008).

This could be due to the viral human molecular mimicry, protein stru[ctural architecture, v](#page-8-0)i[ral pro](#page-9-1)tein mutation and glycosylation. Despite the seri[ous b](#page-9-1)iotechnological challenges there is always an amplified energy to synthesis ENV trimer spike protein.

| <b>GP120</b>     |                          |                |      |  |                                 |                  |      |      |                  |  |  |  |
|------------------|--------------------------|----------------|------|--|---------------------------------|------------------|------|------|------------------|--|--|--|
|                  | Large interfaces van der |                |      | Small interfaces van der waals subdominant |                                 |                  |      |      |                  |  |  |  |
|                  | waals dominant           |                |      |  |                                 |                  |      |      |                  |  |  |  |
| 1G9M             | 2NY4                     | 4R4N           | 1RZ7 | 3IDX                                       | $4$ $ 6R$                       | 4LSS             | 4R4H | 4YBL | 5IES             |  |  |  |
| 1G9N             | 2NY <sub>5</sub>         | 4RFN           | 1RZ8 | 3LQA                                       | $4$ J $B$ 9                     | 4LSU             | 4RQS | 4YC2 | 51F <sub>0</sub> |  |  |  |
| 1GC1             | 2NY <sub>6</sub>         | 4RFO           | 1RZF | 3NGB                                       | 4JDT                            | 4LSV             | 4RWY | 4YDI | 5IGX             |  |  |  |
| 1NAK             | 3JWD                     | 4XNZ           | 1RZG | 3Q6G                                       | $4$ [03                         | 40LU             | 4RX4 | 4YDK | 5KG9             |  |  |  |
| 1RZJ             | 3JWO                     | 4YDJ           | 1RZI | 3SE8                                       | $4$ J $PK$                      | 40LV             | 4S10 | 4YDL | 5T33             |  |  |  |
| 1RZK             | 3MLS                     | 4ZTO           | 1YYL | 3SE9                                       | $4$ $PV$                        | 40LW             | 4S1R | 4YFL | 5TE4             |  |  |  |
| 2F58             | 4DVR                     | 5F96           | 1YYM | 3TYG                                       | 4JPW                            | 40LX             | 4S1S | 5CAY | 5TE <sub>6</sub> |  |  |  |
| 2NXY             | $4$ [01                  | 5KJR           | 2B4C | 3U7Y                                       | $4$ $ZW$                        | 40LY             | 4XMK | 5F6J |                  |  |  |  |
| 2NXZ             | $4$ $102$                | 5KZC           | 215Y | $4$ $[AN$                                  | $4$ $\overline{\phantom{1}}$ zz | 40LZ             | 4XML | 5F90 |                  |  |  |  |
| 2NY <sub>0</sub> | 4K0A                     | 5TE7           | 2160 | 4D9L                                       | 4LAJ                            | 40M <sub>0</sub> | 4XMP | 5F9W |                  |  |  |  |
| 2NY <sub>1</sub> | 4KA2                     | $\blacksquare$ | 2NY7 | 4H <sub>8</sub> W                          | 4LSP                            | 40M1             | 4XNY | 5FCU |                  |  |  |  |
| 2NY <sub>2</sub> | 4LST                     | -              | 20AD | 413R                                       | 4LSQ                            | 4P9H             | 4XVS | 5FEC |                  |  |  |  |
| 2NY3             | 4R4F                     | -              | 3F58 | 413S                                       | 4LSR                            | 4R2G             | 4XVT | 519Q |                  |  |  |  |
|                  |                          |                |      |  |                                 |                  |      |      |                  |  |  |  |

**Table 1: Dataset of GP120 (121) having large (van der Waals Dominant) and small (van der Waals Subdominant) interfaces are listed.**



**Figure 1: Examples of GP120 (PDB 3MLZ) and GP41 (PDB 2ZFC) viral protein interfaces are illustrated along with the percent contribution of each of interface energies.**

The reasonable efficacy shown in the Thai trail vaccine (RV144 - ENV-GP120, Gag and Pro) is promising (Rerks-Ngarm *et al.*, 2009, 2013). Post Thai trial (RV144), the focus is on envelope (ENV) as a vaccine candidate. In addition, ENV GP160 with least homology is selected by performing a sequence comparison [between HIV and human](#page-9-2) [proteo](#page-9-3)me (Kangueane *et al.*, 2008). GP160 ENV trimer spike glycoprotein has gained attention as a potential vaccine candidate in the recent years. Productio[n of native](#page-9-4) like HIV-1 GP160 envelope trimer glycoprotein is a challenge in designing, developing and validating an effective vaccine from a biochemical, structural and immunological view point (Sanders and Moore, 2017; Doores, 2015). Ringe *et al.* (2015) investigated on the number of factors that are importantly influencing the design, stability and purification of native like HIV-1 envelo[pe trimer glycopro](#page-9-5)[tein.](#page-9-5) A[lsalmi](#page-9-6) *e[t al.](#page-9-6)* (2[015\) used st](#page-9-7)r[ep tag](#page-9-7) method to purify GP160 trimer protein and was resulted

|                  |                  |   |                  | GP41                                  |      |      |      |                          |
|------------------|------------------|---|------------------|---------------------------------------|------|------|------|--------------------------|
|                  |                  | Large Interfaces van der Waals Dominant |                  | <b>Small Interfaces van der Waals</b> |      |      |      |                          |
|                  |                  |   |                  | Subdominant                           |      |      |      |                          |
| 1CE <sub>0</sub> | 1U8N             | 2P8L                                    | 3DRT             | 3JW <sub>O</sub>                      | 1NLD | 3MA9 | 4NGH | 5KA6                     |
| 1TJG             | 1U80             | 2P8M                                    | 3EGS             | 3LEX                                  | 1TZG | 3MAC | 4NHC | 5MP6                     |
| 1TJH             | 1U8P             | 2P8P                                    | 3F4Z             | 3LEY                                  | 2CMR | 3MNW | 4U6G | 5U3K                     |
| 1TII             | 1U80             | 2PW1                                    | 3FN <sub>0</sub> | 4NRX                                  | 2FX7 | 3040 | 4XAW | 5U3L                     |
| 1U8H             | 1U <sub>91</sub> | 2PW <sub>2</sub>                        | 3IDG             | 4XC1                                  | 2FX9 | 3043 | 4XBE | 5U3M                     |
| 1U8I             | 1U92             | 2ZFC                                    | 3IDI             | 4XC <sub>3</sub>                      | 2Q3I | 30Z9 | 4XCF | 5U3N                     |
| 1U8J             | 1U93             | 3D <sub>0</sub> L                       | 3IDJ             | 5F89                                  | 2R5B | 3P30 | 5CCK | 5U30                     |
| 1U8K             | 11195            | 3D <sub>0</sub> V                       | 3IDM             | 5U31                                  | 2R5D | 3UIA | 5CMU |                          |
| 1U8L             | 2F5B             | 3DR <sub>0</sub>                        | 3IDN             | $\overline{\phantom{a}}$              | 2X7R | 4KHT | 5IQ7 | $\blacksquare$           |
| 1U8M             | <b>2FX8</b>      | 3DRQ                                    | 3JWD             | $\blacksquare$                        | 3ECB | 4KHX | 5IQ9 | $\overline{\phantom{a}}$ |

**Table 2: Dataset of GP41 (85) having large (van der Waals Dominant) and small (van der Waals Subdominant) interfaces are listed.**

<span id="page-2-0"></span>

**Figure 2: Mean interface size and interface area of GP120 and GP41 protein interfaces.**

<span id="page-2-1"></span>

**Figure 3: Graph showing interfaces with interface area (Å<sup>2</sup> ) for GP120 and GP41.**

with cleaved, uncleaved, fully or partially glycosylated trimers. In addition, they found cleaved gp140 were not required for trimerization, however they played a significant role in triggering conformational changes in channelizing the trimers to generate compact three blade propeller shaped trimers. Verkerke et al. (2016) used lectin affinity chromatography to purify native like trimers from diverse HIV-1 isolates. The challenges faced in the production, analysis and synthesis of GP160 ENV tri[mer glycoprotein are rep](#page-9-9)orted Grimm *et al.* (2015); Guenaga (2015).

Surface mutation, charge polarity and glycosylation and sequence variation between known variants in different clades are the significant barriers causing difficulty in imitating a native-like conformation of the glycoprotein. It is evident that assembling individual GP160 into a trimer spike complex structure is a challenge from a protein-protein interaction viewpoint. A large number of GP120 and GP41 structures are available in the PDB deposited using different biophysical techniques to understand the underlying molecular mechanism of the interacting proteins.

<span id="page-2-2"></span>

**Figure 4: GP120 and GP41 interfaces are shown in terms of mean percent van der Waals, hydrogen bonds and electrostatics.**

Sowmya *et al.* (2011) demonstrated the correlation between sequence polarity and mean Shannon entropy by calculating sequence polarity for surface residues in GP120 and GP41 and concluded stating t[he use of prote](#page-9-11)i[n mod](#page-9-11)ification in the enhancement of HIV-1 vaccine across different clades, blood, and brain. Nilofer *et al.* (2017) characterized the interfaces of GP120-GP120, GP120-GP41 and GP41-GP41 and reported that the interfaces of GP120-GP120 are largely polar. The interfaces of GP120-GP41 and G[P41-GP41 are](#page-9-12) c[harac](#page-9-12)teristics of polar and nonpolar residues. We characterize a manually curated dataset of 121 GP120 and 85 GP41 (Figure 1) pro-

<span id="page-3-0"></span>

**Figure 5: GP120 and GP41 interfaces are shown with varying percent contribution of van der Waals, hydrogen bonds and electrostatics.**

tein interfaces reported by Nilofer *et al.* (2017) using interface features including interface area, interface size (number of residues at the interface), van der Waals, hydrogen bonds and electrostatics, to verify our previous finding statin[g that small protein](#page-9-12) interfaces are rich in electrostatics are often linked to regulatory proteins (Nilofer *et al.*, 2020). The residues at the interface are displayed using CPK depiction (Discovery Studio® (Systèmes, 2020).

## **MATERIALS AN[D METHODS](#page-9-13)**

#### **Dataset**

We used a dataset of 206 interfaces manually curated as reported by Nilofer *et al.* (2017). It consists of 121 GP120 (Table 1) and 85 GP41 (Table 2) interfaces. It should be noted that GP120 structures in the PDB are available in ligand-bound state.

#### **Interface area**

Interface area was estimated for each of 121 interfaces of GP120 and 85 interfaces of GP41 using Naccess (Hubbard and Thornton, 1993). Naccess uses Lee and Richards method (Lee and Richards, 1971), wherein a probe with radius 1.4Å (Jones and Thornton, 1996) roll over the protein complex in monomer state and dimer state to find t[he acc](#page-9-14)essible surface area and the interface ar[ea using delta ASA. Delt](#page-9-15)[a](#page-9-16) ASA (change in accessible surface area) is calculated using a formula: [ASA (Monomer subunit 1) + ASA (Monomer subunit 2) - AB (Dimer complex)]/2.

#### **Interface size & interface energies**

Interface size and interface energies were estimated for each of 121 interfaces of GP120 and GP41 using PPCheck (Sukhwal and Sowdhamini, 2015). PPCheck uses distance criteria to identify the noncovalent interactions between atoms of the two interacting proteins. It should be noted that the role of water is ignor[ed in this analysis.](#page-9-17)

#### **Large interface area and small interface area**

Interfaces with large interface size (98*±*65 (GP120) and 73*±*65 (GP41)) and interface area (882*±*1166Å<sup>2</sup> (GP120) and 921*±*1288Å<sup>2</sup> (GP41)). Having dominant van der Waals energy (*≥*60%) at the interface are defined as large interface whereas interfaces with small interface size (58*±*20 (GP120) and 27*±*9 (GP41)) and interface area (581*±*1605Å<sup>2</sup> (GP120) and  $483\pm896\AA^2$  (GP41)) having subdominant van der Waals energy  $(  $60\%$ ) are defined as$ small interface.

#### **Dominant and subdominant van derWaals interface**

Interfaces with van der Waals contribution *≥*60% to total energy (sum of van der Waals, hydrogen bonds and electrostatics) is defined as dominant interfaces, while interfaces with van der Waals contribution  $<60\%$  to total energy is defined as subdominant interfaces. A cutoff of 60% was used as the larger part of van der Waals contribution was at this cutoff on a scale of 0-100% and hence used.

## **Statistical analysis**

We calculated interface energies of GP120 and GP41 using the statistical (Microsoft<sup>®</sup>Office Excel (version 2003)) variables including mean, mode, distribution, standard deviation and frequency at definite bin and range. We also carried out multiple linear regressions analysis for each interface with interface size against van der Waals, hydrogen bonds, electrostatic, total energy and interface area using regression tool. Its co-efficient of determination (r<sup>2</sup>) was predicted with an evaluation of p-value using ANOVA (statistical test) at 95% confidence limit.

## **RESULTS AND DISCUSSION**

The HIV-1 envelope trimer glycoprotein GP160 is a potential vaccine candidate for HIV-1/AIDS (Burton *et al.*, 2004). Structural data of GP160 available in the PDB are always found to be coupled with ligand shows the degree of stability of GP160 without supportive ligand (Moore *et al.*, 1992).

[The trimer](#page-9-18) interfaces are unstable when produced *invitro* and this may be due to its sequence composition and st[ructural conforma](#page-9-19)tion (Moore *et al.*, 1990; Chen *et al.*, 2005). Nilofer *et al.* (2017) reported that the interfaces of GP120 are largely polar whereas the interfaces of GP120-GP41 and GP41 are characteristics of equal co[ntribution of](#page-9-20) [polar](#page-9-20)a[nd non-pola](#page-9-21)r [residu](#page-9-21)e[s. Interfaces w](#page-9-12)it[h high](#page-9-12) polarity have an immense impact on protein's surface, immunological and stability properties. High polarity at the interface is bottleneck in the *invitro* synthesis and production of GP160 in a stable form. The instability of GP160 could also be due to the complicatedness in mimicking the *invivo* environment in *invitro* for protein folding and assembly of the complex (Abagyan and Batalov, 1997; Kinjo *et al.*, 2001).

Therefore, we characterized the interfaces of GP120 and GP41 using interface area, interface size and interface energies using PPCheck (identifies [non](#page-9-22)[covalent in](#page-9-22)teractions using distance criteria). To verify our pervious findings, we used the manually curated dataset of 121 and 85 interfaces of GP120 and GP41 proteins. The statistical analysis show that the mean interface size (98*±*65 (GP120) and <sup>73</sup>*±*65 (GP41)) and interface area (882*±*1166Å<sup>2</sup>  $(GP120)$  and  $921\pm 1288\AA^2$  (GP41)) to be in close

proximity for GP120 and GP41 interfaces (Figure 2). In contrast to our previous study we observed, most of the interfaces to have an interface area  $\langle 1000 \text{\AA}^2 \rangle$ in both GP120 (60%) and GP41 (71%) and about 25% of GP120 and 19% of GP41 to have interf[ac](#page-2-0)e area between 1500Å $^2$  to 2000Å $^2$  (Figure 3).

Subsequently, we described each interface of GP120 and GP41 using van der Waals, H-bond, electrostatics and total energies along with their v[ar](#page-2-1)ying proportion of contribution at the interface. Thus, we calculated each individual contribution in percentage towards total energy. We observed interfaces to have high percentage of van der Waals (77%) and a low percentage of hydrogen bonds (12%) and electrostatics (11%) on average for GP120 and GP41 complexes (Figure 4). In addition, we noticed the interfaces of GP120 and GP41 to be normally distributed with increasing percentage of van der Waals (Figure 5). While a proportion of the interface decrease with incre[as](#page-2-2)ing percentage of hydrogen bonds and electrostatics unlike van der Waals energy. It should be noted that interfaces of GP120 and GP41 are [s](#page-3-0)imilar with the percentage contribution of van der Waals, hydrogen bonds, electrostatics, interface area and interface size. We further grouped the interfaces of GP120 and GP41 as dominant (*≥*60%) and subdominant (<60%) van der Waals based on its contribution towards total energy. As a result dominant interfaces have *≥*60% of van der Waals with less magnitude of hydrogen bonds and electrostatics.

We observed majority of interfaces of GP120 (88%) and GP41 (74%) to be van der Waals dominant with less that 10% contribution of hydrogen bonds and electrostatics while the remaining 12% of GP120 and 26% of GP41 have subdominant van der Waals with more than 15% of hydrogen bonds and electrostatic (Figure  $6$ ). We performed statistical analysis on dominant van der Waals and subdominant van der Waals interfaces to highlight the contribution of hydrogen bonds and electrostatics in the small interfaces. We observed subdominant van der Waals interfaces of GP120 and GP41 to have three fold more of both hydrogen bonds and electrostatics when compared to dominant van der Waals interfaces (Figure 7). Furthermore, we noticed subdominant van der Waals interfaces to be more pronounced with more than 20% of hydrogen bonds and electrostatics distinct compared to dominant van der Waals in[ter](#page-5-1)faces (Figure 8). It is evident from (Figure 9) that the interface size and interface area of small interfaces are only half when compared to the large interfaces. Most of the interfaces with subdominant van der Waals havei[nt](#page-6-0)erface area less than 500Å $^2$  ([Fi](#page-6-1)gure 10).

<span id="page-5-0"></span>

**Figure 6: GP120 and GP41 interfaces are shown with increasing percentages of van der Waals, hydrogen bonds and electrostatics.**

<span id="page-5-1"></span>

**Figure 7: Mean percentage of hydrogen bonds and electrostatics in large and small interfaces of GP120 and GP41 are shown.**

<span id="page-6-0"></span>

**Figure 8: Percentage of electrostatic and hydrogen bonds in large and small interfaces of GP120 and GP41 are shown.**

<span id="page-6-1"></span>

**Figure 9: Interface size and interface area in large and small interfaces of GP120 and GP41 interfaces are shown.**

Therefore, it was stated that the small interfaces with subdominant van der Waals energy and small interface area are rich in electrostatics.

However, in context to the small interfaces (subdominant van der Waals) of GP120 and GP41, small interfaces of GP120 are rich in hydrogen bonds and GP41 is rich in electrostatics.

Interface size increases with interface area is a known fact and hence we correlated interface size and interface energies.

It was reported that total energy, van der Waals

and hydrogen bonds increase with interface size but electrostatics decrease with increasing interface size (Nilofer *et al.*, 2020).

While the results of our current study shows that van der Waals and total energies of GP120 and GP41 interfaces increase with interface size but hydrogen bond[s and electrostatic](#page-9-13)s decrease with increasing interface size (Figure 11).

Hence we divided our interfaces as large (dominant van der Waals) and small (subdominant van der Waals) interface based on their percent contribution towards total energy [to c](#page-7-0)heck for correlation.



<span id="page-7-0"></span>**Figure 10: Interface area in large and small interfaces among GP120 and GP41 is shown.**



**Figure 11: Correlation between interface energy and interface size of GP120 and GP41 interfaces is shown.**

<span id="page-8-2"></span>

**Figure 12: Correlation between interface energy and interface size for GP120 and GP41 interfaces in terms of large and small interfaces is shown.**

It has also been reported that in small interfaces, total energy, van der Waals and hydrogen bonds decreases considerably with the increasing interface size whereas electrostatics moderately increases with interface size (Nilofer *et al.*, 2020). But, this is not the case with the small interfaces of GP120 and GP41. Surprisingly, we found electrostatics ( $r^2$ =0.63) (Figure 12p) to be highly pronounced in GP41 interfaces w[ith subdominant va](#page-9-13)n der Waals having van der Waals  $(r^2=0.23)$  (Figure 12h) and without hydrogen bonds  $(r^2=0)$  (Figure 12p) contribution. Con[tras](#page-8-2)tingly, we observed the small interfaces of GP120 to be highly stabilized by hydrogen bonds ( $r^2$ =0.59) (Figure 12k) followed by [elec](#page-8-2)trostatics  $(r^2=0.20)$  (Figure 12o). Hence, we rep[ort](#page-8-2) that hydrogen bonds  $(r^2=0.59)$  (Figure 12k) increases with the interface size in the small interfaces of GP120 and electrostatics  $(r^2=0.63)$  $(r^2=0.63)$  $(r^2=0.63)$  (Figure 12p) increases with the inte[rfac](#page-8-2)e size i[n th](#page-8-2)e small interfaces of GP41.

### **CONCLUSIONS**

GP1[20](#page-8-2) viral proteins interact with GP41 to form GP160 the HIV-1 trimer glycoprotein. Statistical analysis on the interfaces of GP120 and GP41 using interface area, interface size and interface energies including van der Waals, hydrogen bonds and electrostatics demonstrate that they are similar. 88% of GP120 and 74% of GP41 interfaces have large interface area and interface size with dominant van der Waals energy; while 12% of GP120 and 26% of

GP41 interfaces have small interface area and interface size with subdominant van der Waals energy. In addition, small interfaces were observed to have three fold more of hydrogen bonds and electrostatics than large interfaces. It is shown hydrogen bonds to increase with interface size in the small interfaces of GP120; while electrostatics to increase with interface size in small interfaces of GP41 in absence of hydrogen bonds. These insights from the interfaces of GP120 and GP41 shows that our previous finding stating that small interfaces with small interface area are rich in electrostatics holds true in case of GP41 but not in the case of GP120.

#### **Funding Support**

The authors declare that they have no funding support for this study.

#### **Conϐlict of Interest**

The authors declare that they have no conflict of interest for this study.

#### **REFERENCES**

- Abagyan, R. A., Batalov, S. 1997. Do aligned sequences share the same fold. *Journal of Molecular Biology*, 273(1):355–368.
- <span id="page-8-1"></span><span id="page-8-0"></span>Adis Editorial 2003. HIV gp120 Vaccine-VaxGen: AIDSVAX<sup>TM</sup>, AIDSVAX<sup>TM</sup> B/B, AIDSVAX<sup>TM</sup> B/E, HIV gp120 Vaccine-Genentech, HIV gp120 Vaccine AIDSVAX-VaxGen, HIV Vaccine AIDSVAX-VaxGen. *Drugs in R & D*, 4:249–253.
- <span id="page-9-8"></span>Alsalmi, W., *et al.* 2015. A New Approach to Produce HIV-1 Envelope Trimers. *Journal of Biological Chemistry*, 290(32):19780–19795.
- <span id="page-9-18"></span>Burton, D. R., *et al.* 2004. HIV vaccine design and the neutralizing antibody problem. *Nature Immunology*, 5(3):233–236.
- <span id="page-9-21"></span>Chen, B., *et al.* 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. *Nature*, 433(7028):834–841.
- <span id="page-9-6"></span>Doores, K. J. 2015. The HIV glycan shield as a target for broadly neutralizing antibodies. *FEBS Journal*, 282(24):4679–4691.
- <span id="page-9-10"></span>Grimm, S. K., *et al.* 2015. Directed Evolution of a Yeast-Displayed HIV-1 SOSIP gp140 Spike Protein toward Improved Expression and Affinity for Conformational Antibodies. *PLOS ONE*, 10(2).
- Guenaga, J. 2015. Well-ordered trimeric hiv-1 subtype b and c soluble spike mimetics generated by negative selection display native-like properties. *PLoS Pathogens*, 11(1).
- <span id="page-9-14"></span>Hubbard, S. J., Thornton, J. M. 1993. NACCESS Computer Program. *Journal of Biophysical Chemistry*, 1(3).
- <span id="page-9-16"></span>Jones, S., Thornton, J. M. 1996. Principles of proteinprotein interactions. *Proceedings of the National Academy of Sciences*, 93(1):13–20.
- <span id="page-9-4"></span>Kangueane, P., *et al.* 2008. Designing HIV gp120 peptide vaccines: Rhetoric or reality for Neuro-AIDS. *Spectrum of Neuro-AIDS Disorders*, pages 105–119.
- <span id="page-9-22"></span>Kinjo, A. R., *et al.* 2001. Physicochemical evaluation of protein folds predicted by threading. *European Biophysics Journal*, 30(1):1–10.
- <span id="page-9-15"></span>Lee, B., Richards, F. M. 1971. The interpretation of protein structures: Estimation of static accessibility. *Journal of Molecular Biology*, 55(3):379–383.
- <span id="page-9-20"></span>Moore, J. P., *et al.* 1990. Enhancement of soluble CD4-mediated HIV neutralization and gp120 binding by CD4 autoantibodies and monoclonal antibodies. *AIDS Research and Human Retroviruses*, 6(11):1273–1279.
- <span id="page-9-19"></span>Moore, J. P., *et al.* 1992. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. *Journal of Virology*, 66(1):235–243.
- <span id="page-9-12"></span>Nilofer, C., *et al.* 2017. HIV-1 envelope (ENV) GP160 trimer protein complex SPIKE as a recombinant macromolecular assembly vaccine component candidate: Current opinion. *Global Virology II - HIV and NeuroAIDS*, pages 939–951.

<span id="page-9-13"></span>Nilofer, C., *et al.* 2020. Small protein-protein inter-

faces rich in electrostatic are often linked to regulatory function. *Journal of Biomolecular Structure and Dynamics*, 38(11):3260–3279.

- <span id="page-9-2"></span>Rerks-Ngarm, S., *et al.* 2009. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. *New England Journal of Medicine*, 361(23):2209–2220.
- <span id="page-9-3"></span>Rerks-Ngarm, S., *et al.* 2013. Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. *Journal of Infectious Diseases*, 207(8):1195– 1205.
- <span id="page-9-7"></span>Ringe, R. P., *et al.* 2015. Influences on the design and purification of soluble, recombinant nativelike HIV-1 envelope glycoprotein trimers. *Journal of Virology*, 89(23):12189–12210.
- <span id="page-9-5"></span>Sanders, R. W., Moore, J. P. 2017. Native-like Env trimers as a platform for HIV-1 vaccine design. *Immunological Reviews*, 275(1):161–182.
- <span id="page-9-0"></span>Shin, S. Y. 2016. Recent update in HIV vaccine development. *Clinical and Experimental Vaccine Research*, 5(1):6.
- <span id="page-9-11"></span>Sowmya, G., *et al.* 2011. HIV-1 envelope accessible surface and polarity: clade, blood, and brain. *Bioinformation*, 6(2):48–56.
- <span id="page-9-17"></span>Sukhwal, A., Sowdhamini, R. 2015. PPCheck: A webserver for the quantitative analysis of protein interfaces and prediction of residue hotspots. *Bioinformatics and Biology Insights*, 9:141–151.
- Systèmes, D. 2020. BIOVIA, discovery studio visualizer, release 2019. *San Diego: Dassault Systèmes*.
- <span id="page-9-1"></span>Überla, K. 2008. HIV vaccine development in the aftermath of the STEP study: Re-focus on occult hiv infection? *PLoS Pathogens*, 4(8):e1000114.
- <span id="page-9-9"></span>Verkerke, H. P., *et al.* 2016. Epitope independent purification of native like envelope trimers from diverse HIV-1 isolates. *Journal of Virology*, 90(20):9471–9482.